{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:47:38Z","timestamp":1764251258683,"version":"3.41.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1111\/igc.0b013e3181e8df36","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T14:29:09Z","timestamp":1291386549000},"page":"1137-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial"],"prefix":"10.1016","volume":"20","author":[{"given":"Russell J.","family":"Schilder","sequence":"first","affiliation":[]},{"given":"John A.","family":"Blessing","sequence":"additional","affiliation":[]},{"given":"Mark S.","family":"Shahin","sequence":"additional","affiliation":[]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[]},{"given":"Krishnansu Sujata","family":"Tewari","sequence":"additional","affiliation":[]},{"given":"Carolyn Y.","family":"Muller","sequence":"additional","affiliation":[]},{"given":"David P.","family":"Warshal","sequence":"additional","affiliation":[]},{"given":"Scott","family":"McMeekin","sequence":"additional","affiliation":[]},{"given":"Jacob","family":"Rotmensch","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181e8df36_bb0005","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0010","series-title":"Gynecologic Oncology","first-page":"895","article-title":"Epithelial ovarian cancer","author":"Ozols","year":"2005"},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0015","series-title":"Cancer. Principles & Practice of Oncology","first-page":"1364","article-title":"Ovarian cancer, peritoneal carcinoma, and fallopian tube carcinoma","author":"Karlan","year":"2005"},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0020","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0006-2952(97)00321-3","article-title":"Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114)","volume":"54","author":"Woynarowski","year":"1997","journal-title":"Biochem Pharmacol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0006-2952(02)01552-6","article-title":"Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2Yindependent","volume":"65","author":"Herzig","year":"2003","journal-title":"Biochem Pharmacol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0006-2952(99)00085-4","article-title":"Drug uptake and cellular targets of hydroxy methylacylfulvene (HMAF)","volume":"58","author":"Herzig","year":"1999","journal-title":"Biochem Pharmacol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0035","first-page":"279","article-title":"Preclinical antitumor activity of 6-hydroxymethlacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S","volume":"57","author":"MacDonald","year":"1997","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-008-0703-0","article-title":"Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model","volume":"63","author":"Kelner","year":"2008","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0045","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00280-005-0063-y","article-title":"Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells","volume":"57","author":"Serova","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/B:DRUG.0000026262.77502.31","article-title":"Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group","volume":"22","author":"Schilder","year":"2004","journal-title":"Invest New Drugs."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0055","first-page":"20","article-title":"Phase II study of irofulven in platinum resistant recurrent ovarian cancer. Proc Am Soc","author":"Sarosy","year":"2001","journal-title":"Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2005.09.036","article-title":"A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer","volume":"101","author":"Seiden","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0065","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-03-0349","article-title":"Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients","volume":"10","author":"Alexandre","year":"2004","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0075","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00000421-198308000-00008","article-title":"Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary: a phase II study of the Gynecologic Oncology Group","volume":"6","author":"Thigpen","year":"1983","journal-title":"Am J Clin Oncol: Cancer (CCT)."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0080","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0085","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat Med."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archopht.123.1.29","article-title":"Cone damage in patients receiving high-dose irofulven treatment","volume":"123","author":"Lee","year":"2005","journal-title":"Arch Ophthalmol."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0095","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1158\/1078-0432.CCR-04-0869","article-title":"Characterization and multiparameter analysis of visual adverse events in irofulven single agent phase I and II trials","volume":"10","author":"Raymond","year":"2004","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0100","first-page":"3796s","article-title":"Irofulven in combination with irinotecan: a phase I study examining three schedules in patients with advanced cancers","volume":"7","author":"Debono","year":"2001","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181e8df36_bb0105","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.canlet.2008.02.048","article-title":"Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven","volume":"265","author":"Dings","year":"2008","journal-title":"Cancer Lett."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181e8df36","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24037277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24037277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:17:46Z","timestamp":1753233466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24037277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1048891X24037277"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181e8df36","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181e8df36","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}